Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Af­ter wrestling with the San­doz prob­lem for sev­er­al years, Vas Narasimhan set­tles on a spin­out

No­var­tis CEO Vas Narasimhan has fi­nal­ly fig­ured out how he can get San­doz off his list of ma­jor headaches. He’s go­ing to spin the gener­ics gi­ant out as a sep­a­rate com­pa­ny.

The phar­ma gi­ant says it will set up San­doz as an in­de­pen­dent com­pa­ny in H2 2023 af­ter nav­i­gat­ing the sep­a­ra­tion through reg­u­la­tors. The spin­out will cre­ate a lum­ber­ing gi­ant with a home on the SIX Swiss Ex­change, an Amer­i­can De­posi­tary Re­ceipt pro­gram in the US, a pipeline of 15 biosim­i­lars and a rep for mediocre per­for­mance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.